Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03097341 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects
A Phase 1 study, sponsored by Aronora.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03097341: Completed Phase 1 study, sponsored by Aronora.
NCT03097341 is a Phase 1 study that has completed, run by Aronora. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03097341, a Phase 1 study, has completed, sponsored by Aronora.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of xisomab 3G3 in healthy adult subjects.
Primary Outcome
TEAEs will be determined by physical examination that will include assessment of skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system.
Interventions
- OTHER Placebo
- DRUG xisomab 3G3- Dose 1
- DRUG xisomab 3G3-Dose 2
- DRUG xisomab 3G3-Dose 3
- DRUG xisomab 3G3- Dose 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-06-05 |
| Est. Completion | 2018-01-16 |
| Phase | Phase 1 |
What the finished NCT03097341 record still lists
NCT03097341 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03097341 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03097341 about?
NCT03097341 is a clinical study titled "Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects". The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of xisomab 3G3 in healthy adult subjects.
What is the current status of trial NCT03097341?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-06-05. Estimated completion is 2018-01-16.
What interventions are being tested in trial NCT03097341?
The interventions under investigation include: Placebo (OTHER), xisomab 3G3- Dose 1 (DRUG), xisomab 3G3-Dose 2 (DRUG), xisomab 3G3-Dose 3 (DRUG), xisomab 3G3- Dose 4 (DRUG).
Who is sponsoring clinical trial NCT03097341?
This trial is sponsored by Aronora, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03097341's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI